Clinically Guided
GLP-1 Therapy Access
Aspen GLP is a medical access platform that connects individuals with licensed healthcare providers for evaluation and access to compounded GLP-1 and GLP-1/GIP therapies. Every therapy option is considered based on medical history, clinical eligibility, and provider oversight to support informed care decisions.
Medical Evaluation Comes First
Aspen GLP operates with a consultation-first model. We do not sell medications directly. Instead, we facilitate evaluations by licensed healthcare providers to determine whether compounded GLP-1 therapy is appropriate given individual clinical factors.
Our approach prioritizes safety screening, provider involvement, and clear information so individuals understand therapy options before moving forward.
Key Highlights:
Licensed healthcare provider evaluations
Eligibility-based therapy consideration
Ongoing clinical oversight throughout care
Medically Reviewed Therapy Options
Aspen GLP provides access to compounded GLP-1 and GLP-1/GIP therapies following a medical consultation. Each therapy option is reviewed by a licensed healthcare provider to determine appropriateness based on medical history, safety considerations, and clinical goals.
Injectable Semaglutide Therapy Option
Compounded Injectable Semaglutide is a GLP-1 receptor agonist therapy administered through subcutaneous injection. It is evaluated for individuals seeking provider-guided therapy options that support appetite regulation and metabolic processes. Use is determined through medical review and ongoing supervision.
Oral Semaglutide Therapy Option
Compounded Oral Semaglutide provides a non-injectable GLP-1 therapy option for individuals who prefer oral administration. This therapy is evaluated clinically and requires provider oversight to ensure appropriate use and safety monitoring.
Injectable Tirzepatide Therapy Option
Compounded Injectable Tirzepatide is a dual GLP-1 and GIP receptor agonist therapy evaluated for individuals who may benefit from a dual-pathway approach. Treatment decisions are made by licensed healthcare providers after a medical consultation.
Oral Tirzepatide Therapy Option
Compounded Oral Tirzepatide is an oral formulation of a dual GLP-1 and GIP receptor agonist. This option is reviewed following a medical consultation and is prescribed based on individual eligibility and provider guidance.
A Structured, Provider-Led Process
Aspen GLP follows a defined, provider-guided process to support safe, informed therapy decisions.
Process Overview:
Medical Consultation
Review of medical history and current health considerations
Provider Oversight
Ongoing supervision by licensed healthcare professionals
Therapy Review
Discussion of clinically appropriate compounded GLP-1 options
Monitoring
Continued assessment of response, tolerability, and safety
Why Patients Choose Aspen GLP
Aspen GLP is built around a medical-first approach focused on evaluation, safety, and provider oversight. Every step of the process is designed to support informed decision-making, appropriate therapy selection, and ongoing clinical guidance rather than transactional treatment access.
Eligibility Is Determined Clinically
A consultation allows a licensed healthcare provider to review medical history, assess potential risks, and determine whether compounded GLP-1 therapy is appropriate. No therapy option is recommended without clinical evaluation.
Informed Decisions
Understanding Therapy Before Treatment
GLP-1 and GLP-1/GIP receptor agonist therapies are prescribed to support appetite regulation and metabolic processes. These therapies require medical supervision and are considered based on individual clinical profiles, safety considerations, and provider evaluation.